These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 24794806

  • 1. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
    Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F.
    Leuk Lymphoma; 2015 Feb; 56(2):395-400. PubMed ID: 24794806
    [Abstract] [Full Text] [Related]

  • 2. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L.
    Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
    [Abstract] [Full Text] [Related]

  • 3. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
    Bourrié B, Brassard DL, Cosnier-Pucheu S, Zilberstein A, Yu K, Levit M, Morrison JG, Perreaut P, Jegham S, Hilairet S, Bouaboula M, Penarier G, Guiot C, Larroze-Chicot P, Laurent G, Demur C, Casellas P.
    Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ.
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib - a small molecule with big promise?
    Tadmor T, Tallman MS, Polliack A.
    Leuk Lymphoma; 2010 Feb; 51(2):181-2. PubMed ID: 20001865
    [No Abstract] [Full Text] [Related]

  • 6. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
    Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE.
    Blood; 2003 Aug 01; 102(3):795-801. PubMed ID: 12649163
    [Abstract] [Full Text] [Related]

  • 7. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
    Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H.
    Clin Cancer Res; 2004 May 01; 10(9):2908-17. PubMed ID: 15131024
    [Abstract] [Full Text] [Related]

  • 8. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H.
    Cancer; 2016 Jun 15; 122(12):1871-9. PubMed ID: 26990290
    [Abstract] [Full Text] [Related]

  • 9. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2012 Aug 15; 12(4):244-51. PubMed ID: 22534616
    [Abstract] [Full Text] [Related]

  • 10. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW, Chen HW, Hedley DW, Chow S, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Sanfelice D, Johnson T, Le LW, Arnott J, Bray MR, Sidor C, Minden MD.
    Invest New Drugs; 2016 Oct 15; 34(5):614-24. PubMed ID: 27406088
    [Abstract] [Full Text] [Related]

  • 11. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.
    Leuk Res; 2006 Jul 15; 30(7):813-22. PubMed ID: 16478631
    [Abstract] [Full Text] [Related]

  • 12. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX.
    Int J Hematol; 2005 Jul 15; 82(1):48-54. PubMed ID: 16105759
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
    Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H.
    J Clin Oncol; 2005 Apr 20; 23(12):2805-12. PubMed ID: 15728224
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
    Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA, Alliance for Clinical Trials in Oncology.
    Invest New Drugs; 2013 Oct 20; 31(5):1311-20. PubMed ID: 23700288
    [Abstract] [Full Text] [Related]

  • 15. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.
    Br J Haematol; 2014 Oct 20; 167(2):185-93. PubMed ID: 25040094
    [Abstract] [Full Text] [Related]

  • 16. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
    Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C.
    Leuk Lymphoma; 2017 Aug 20; 58(8):1880-1886. PubMed ID: 27911138
    [Abstract] [Full Text] [Related]

  • 17. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC.
    J Clin Oncol; 2011 Mar 10; 29(8):979-85. PubMed ID: 21282541
    [Abstract] [Full Text] [Related]

  • 18. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.
    Lancet Oncol; 2015 Sep 10; 16(9):1099-1110. PubMed ID: 26296954
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 10; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 20. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.
    Cancer; 2018 Jan 15; 124(2):306-314. PubMed ID: 28960265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.